Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

273TiP - ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788

Date

10 Sep 2022

Session

Poster session 02

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Sara Hurvitz

Citation

Annals of Oncology (2022) 33 (suppl_7): S88-S121. 10.1016/annonc/annonc1040

Authors

S.A. Hurvitz1, K. Kalinsky2, D. Tripathy3, G. Sledge4, W.J. Gradishar5, J. O'Shaughnessy6, S. Modi7, H. Park8, A. McCartney9, S. Frentzas10, C. Shannon11, K. Cuff12, R.W. Eek13, M. Martin Jimenez14, G. Curigliano15, G. Jerusalem16, C. Huang17, M. Press18, J. Lu19

Author affiliations

  • 1 Medicine/hematology Oncology Dept., UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US
  • 2 Medicine, Columbia University Vagelos College of Physicians and Surgeons, 10032-3784 - New York/US
  • 3 Breast Medical Oncology Dept., The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 4 Oncology Department, Stanford University, 94305 - Stanford/US
  • 5 Hematology And Oncology, Northwestern University Feinberg School of Medicine, 60611 - Chicago/US
  • 6 Oncology Department, Texas Oncology - Baylor Sammons Cancer Center, 75246 - Dallas/US
  • 7 Oncology Department, Memorial Sloan Kettering Cancer Center, 10065 - New York, NY/US
  • 8 Oncology Department, Washington University School of Medicine, 63110 - St. Louis/US
  • 9 Medical Oncology Department, Monash Health - Monash Medical Centre, 3168 - Clayton/AU
  • 10 Medical Oncology Department, Monash Health - Monash Cancer Centre, 3165 - Bentleigh East/AU
  • 11 Medical Oncology, Mater Cancer Care Centre, 4101 - Brisbane/AU
  • 12 Oncology Department, Princess Alexandra Hospital, 4102 - Brisbane/AU
  • 13 Medical Oncology Department, Border Medical Oncology Murray Valley Private Hospital, 3690 - Wodonga/AU
  • 14 Servicio De Oncologia Médica Department, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 15 Early Drug Development for Innovative Therapies Division, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 16 Medical Oncology Department, Centre Hospitalier Universitaire Sart Tilman, 4000 - Liège/BE
  • 17 Surgery Dept., NTUH - National Taiwan University Hospital, 10002 - Taipei City/TW
  • 18 Pathology, Keck School of Medicine - University of Southern California USC, 90033 - Los Angeles/US
  • 19 Medicine Dept., USC - University of Southern California - Norris Comprehensive Cancer Center, 90033 - Los Angeles/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 273TiP

Background

The HER2 receptor is an oncogenic driver that is overexpressed on 15-20% of breast cancers. HER2+ targeted therapy has improved survival in both early and advanced disease, but new treatments are needed for recurrent and refractory disease. ARX788 is a next-generation ADC using a HER2-specific monoclonal antibody conjugated with Amberstatin269, a potent cytotoxic tubulin inhibitor (DAR=2). Site-specific, highly homogenous, and stable covalent conjugation leads to slow release and prolonged peak of serum pAF-AS269, with lower systemic toxicity, increased targeted delivery, and lower effective dose. Previous study, ACE-Breast-01 had a confirmed ORR of 16/29 (66%) and a DCR of 29/29 (100%) in the 1.5 mg/kg cohort. ARX788 was generally well tolerated with most adverse events being Grade 1 or 2 and manageable.

Trial design

ACE-Breast-03 is a global, single arm, phase II study assessing anticancer activity and safety of ARX788 in patients with metastatic HER2 positive BC. Patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens are eligible. Brain metastasis must be radiographically stable and steroid independent. Patients must have adequate organ function. In the safety lead-in, subjects (n=20) will be randomized between 2 dosages (1.6 mg/kg or 1.7 mg/kg Q3W). After RP2D, approximately 200 subjects with advanced HER2-positive BC will be enrolled in the main study. Efficacy will be assessed using RECIST 1.1 via imaging every 6 weeks. Primary endpoint is ORR, and secondary endpoints include DOR, TR, BOR, DCR, PFS, and OS. Safety and tolerability will be assessed. Blood samples will be collected at specified time points to determine serum concentrations of ARX788 (intact ADC), total antibody, and metabolite pAF-AS269. Biomarkers (e.g., cfDNA, serum HER2 extracellular domain, others) at baseline and on-treatment will be analyzed for exploratory research. Descriptive statistics will be used to evaluate anticancer activity, safety, and tolerability. The first patient enrolled in 07-Feb-2022 under protocol version 2. The study is currently recruiting patients.

Clinical trial identification

NCT04829604 EudraCT 2021-001246-36.

Editorial acknowledgement

Darryl Z. L'Heureux, Ambrx.

Legal entity responsible for the study

Ambrx, Inc.

Funding

Ambrx, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.